Patent ID: 8691275

Claim:
A controlled-release medicament composition comprising melatonin dispersed in a controlled melatonin release portion comprising a polymer matrix, the polymer matrix adapted to encapsulate the melatonin in a melatonin solubility enhancing pH environment and to maintain the melatonin solubility enhancing pH environment when the composition is located in a melatonin solubility diminishing pH environment for allowing an effective amount of melatonin to be released into the melatonin solubility diminishing pH environment; wherein the composition is in an oral dosage form that can be administered to a patient; wherein the dosage form releases approximately 50% of the melatonin within approximately 1-3 hours after being administered to the patient and releases approximately 50-90% of the remaining melatonin between approximately 3-9 hours after being administered to the patient; and wherein the melatonin solubility enhancing pH environment is an acidic pH environment having a pH of 2-4.